World-Renowned Retinal Specialist joins iCo Therapeutics' Strategic Advisory Team

Mar 02, 2006, 00:00 ET from iCo Therapeutics Inc.

    VANCOUVER, March 2 /PRNewswire/ - iCo Therapeutics Inc. announced today
 that Dr. Alan Bird has joined iCo's Strategic Advisory Team. A pioneer in
 ophthalmic research, teaching and clinical medicine, Dr. Bird's contributions
 to the field of retinal disease have met with worldwide acclaim.
     "We are thrilled to have such a respected advisor on our team," said
 Andrew Rae, iCo President and CEO. "His knowledge and experience will be
 invaluable as we continue to seek out and license cutting-edge products to
 build our ophthalmology portfolio."
     Dr. Bird's esteemed career began at Moorfield's Eye Hospital in London,
 England where his contributions to the treatment of retinal vascular disease
 and genetic & degenerative retinal disorders were at the forefront of the
 field. From Moorfield's, his academic career took him to the Bascom Palmer Eye
 Institute and Jules Stein Eye Center in the United States. He returned to
 London and spent the majority of his career at the Institute of Ophthalmology
 at University College London and Moorfield's Eye Hospital where, in
 collaboration with Professor Shomi Bhattacharya, Dr. Bird identified numerous
 eye disease genes and cemented the standing of the University College London
 and Moorfield's Eye Hospital as one of the top eye research and care centers
 worldwide. Dr. Bird also spent time in Africa undertaking research into river
 blindness, where his work led to the establishment of Ivermectin as the
 treatment of choice for this disease.
     Dr. Bird's expertise has been widely sought after and he has made
 strategic contributions to the US National Eye Institute, the UK Medical
 Research Council, the Wellcome Trust, INSERM and Deutsche
 Forschungsgemeinschaft. He has also played a key role in the design and
 evaluation of numerous clinical trials involving ground-breaking treatments in
 retinal disease today. Most recently, Dr. Bird chaired the Independent Data
 Safety and Monitoring Committee for the pegaptanib pivotal trial for
 age-related macular degeneration.
     "iCo's business model of developing pre-existing drugs for diseases of
 the eye has significant potential," said Dr. Bird. "I look forward to helping
 with the clinical trial design of these products, beginning with the antisense
 compound iCo 007."
     Dr. Bird is a Fellow of the UK National Academy of Medical Science and
 has received a number of prestigious awards in vision science and
 ophthalmology, including the Alcon Research Award, The Helen Keller Prize, the
 Kayser Award, and the Jules Francois Medal. In 2006, he was honored with the
 lifetime achievement award by the Macular Society.
     iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
 company focused on developing pre-existing drugs for a range of new conditions
 affecting isolated biological environments - areas such as the eye, spinal
 cord, or joints - where locally-administered application of these therapies
 would have minimal systemic distribution and fewer safety issues.
     For more information, visit the company website at
     Business Development Contact:           Finance/Investor Contact:
     Dr. John Clement, CTO                   Mr. John Meekison, CFO
     778.688.0644                            604.602.9414
     Media Contact:
     Elayne Wandler,
     ABLE Communications

SOURCE iCo Therapeutics Inc.